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Abstract The vascular system has the critical function of
supplying tissues with nutrients and clearing waste prod-
ucts. To accomplish these goals, the vasculature must be
sufﬁciently permeable to allow the free, bidirectional pas-
sage of small molecules and gases and, to a lesser extent, of
plasma proteins. Physiologists and many vascular biolo-
gists differ as to the deﬁnition of vascular permeability and
the proper methodology for its measurement. We review
these conﬂicting views, ﬁnding that both provide useful but
complementary information. Vascular permeability by any
measure is dramatically increased in acute and chronic
inﬂammation, cancer, and wound healing. This hyperper-
meability is mediated by acute or chronic exposure to
vascular permeabilizing agents, particularly vascular per-
meability factor/vascular endothelial growth factor (VPF/
VEGF, VEGF-A). We demonstrate that three distinctly
different types of vascular permeability can be distin-
guished, based on the different types of microvessels
involved, the composition of the extravasate, and the
anatomic pathways by which molecules of different size
cross-vascular endothelium. These are the basal vascular
permeability (BVP) of normal tissues, the acute vascular
hyperpermeability (AVH) that occurs in response to a sin-
gle, brief exposure to VEGF-A or other vascular
permeabilizing agents, and the chronic vascular hyperper-
meability (CVH) that characterizes pathological angio-
genesis. Finally, we list the numerous (at least 25) gene
products that different authors have found to affect vas-
cular permeability in variously engineered mice and
classify them with respect to their participation, as far as
possible, in BVP, AVH and CVH. Further work will be
required to elucidate the signaling pathways by which each
of these molecules, and others likely to be discovered,
mediate the different types of vascular permeability.
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Introduction
All cells require a continuing supply of nutrients and a
means of clearing waste products. Single cells achieve
these necessities by exchanging gases and small molecules
directly with their environment by diffusion. However,
vertebrates have solved the problems of nutrition and waste
disposal by developing a vascular system that extends into
all organs and tissues. While the vascular system of higher
organisms is often described as ‘‘closed’’, it needs to be
sufﬁciently ‘‘open’’ (i.e., ‘‘permeable’’) to allow the ready
exchange of small molecules (gases, nutrients, waste
products) with the tissues. Plasma proteins also need to
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Albumin, for example, transports fatty acids and vitamins
and immunoglobulin antibodies are required for host
defense.
Vascular permeability, then, is essential for the health
of normal tissues and is also an important characteristic
of many disease states in which it is greatly increased.
Examples are acute inﬂammation and pathologies asso-
ciated with angiogenesis such as tumors, wounds, and
chronic inﬂammatory diseases [1–4]. However, there is
considerable disagreement as to the meaning of the term
vascular permeability and the methods by which it
should be measured [5]. Also, permeability is an extre-
mely complicated process that, however deﬁned, is
affected by many different variables. These include the
intrinsic properties of the different types of microvessels
involved (capillaries, venules, mother vessels(MV)); the
size, shape, and charge of extravasating molecules; the
anatomic pathways molecules take in crossing the
endothelial cell barrier; the time course over which
permeability is measured; and the animals and vascular
beds that are being investigated. This review addresses
these issues with the hope that investigators in different
ﬁelds will be able to communicate more effectively with
each other and better measure and evaluate the signiﬁ-
cance of vascular permeability in normal physiology and
in various pathologic states. A closely related issue, that
of the passage of inﬂammatory cells across the micro-
vasculature, is discussed elsewhere [6–8].
What is vascular permeability and how should
it be measured?
The physiologists’ view of vascular permeability
Surprisingly, there is not good agreement as to what is
meant by the term ‘‘vascular permeability’’ and from this it
follows that there is no consensus about how vascular
permeability should be measured. Over the last half-cen-
tury eminent physiologists including Pappenheimer,
Landis, Starling, Renkin, Michel, Curry, Rippe, and Bates
have investigated the mechanisms by which plasma and its
solutes cross the vascular barrier [5, 9–13]. They recog-
nized that capillaries were the vascular segment involved in
molecular exchange in normal tissues and that gases, water,
and other small molecules crossed the capillary endothelial
cell barrier freely whereas the passage of larger molecules
such as plasma proteins was tightly restricted. Physiolo-
gists have commonly regarded capillary endothelium as a
passive barrier, a thin, cellophane-like membrane that is
punctuated by large numbers of small pores and lesser
numbers of large pores. They postulated that the numerous
small pores allowed the ready passage of small molecules
and that the lesser number of large pores allowed limited
extravasation of plasma proteins. With these assumptions
in mind they developed elegant methods for investigating
the ﬂux of water and of plasma solutes across individual
cannulated microvessels. They developed equations to
calculate the three parameters that determine permeability,
namely, hydraulic conductivity, reﬂection coefﬁcient, and
diffusion. Diffusion is the most important of these for the
exchange of small molecules and is driven by the molec-
ular concentration gradient across vascular endothelium as
determined by the Fick equation:
Js ¼ DA=T Cv   Ci ðÞ
where Js is the diffusion rate (e.g., ml/s) of a particular
solute; D is the diffusion coefﬁcient for that solute; A is
surface area available for exchange; T is the thickness of
the capillary; and Cv-Ci is the difference in solute con-
centration between the plasma and the interstitial ﬂuid.
The value of D in the Fick equation depends heavily on
molecular size; for example, the diffusion of albumin
across the vasculature is estimated to be *1,000-fold less
than that of water [11, 12]. As a result, ﬁltration is much
more important than diffusion for the ﬂux of large mole-
cules such as plasma proteins and is determined by the
Starling equation:
Jv ¼ LpA Pv   Pi ðÞ   rp v   pi ðÞ ½ 
where Jv is ﬁltration rate (e.g., ml/s); LP is hydraulic con-
ductivity or the ﬁltration coefﬁcient, a property of the
capillary wall and a measure of capillary permeability to
water; A is surface area available for molecular exchange;
Pv-Pi and pv-pi are, respectively, the hydrostatic and
osmotic pressure differences between the plasma and the
interstitium; and r is the osmotic reﬂection or solvent-drag
reﬂection coefﬁcient. r varies in different tissues from 0 to
1 and tissues such as skin with high values (e.g., 0.9)
permit little plasma-protein escape. Further details con-
cerning the diffusion and Starling equations can be found
in standard textbooks of Physiology and in several excel-
lent reviews [12–16].
Permeability as understood by vascular biologists
In contrast to physiologists, vascular biologists have used
the term vascular permeability in a less restrictive sense.
Rather than being concerned with the permeability of a
single cannulated microvessel, they have sought to measure
the net amount of a solute, typically a macromolecule such
as plasma albumin, that has crossed a vascular bed and
accumulated in the interstitium in response to a vascular
permeabilizing agent or at a site of pathological angio-
genesis. Generally speaking, the vessels involved are not of
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ther all of the factors, both intrinsic properties of the blood
vessels as well as extrinsic properties such as blood ﬂow,
that regulate extravasation.
To obtain this type of information, they have generally
used the Miles assay or one of its variants [17–19]. Typi-
cally, a dye such as Evan’s blue that binds noncovalently to
albumin is injected intravenously and its accumulation is
measured at some later time at a skin test site (Fig. 1), in a
tumor, or in other tissues of interest. Permeability is deﬁned
as the amount of albumin–dye complex that is present at
some time (often 30 min) after Evan’s blue injection. The
intensity of local bluing observed visually provides sufﬁ-
cient information for some purposes. For example, local
bluing in guinea pig skin was used to evaluate column
fractions in the original puriﬁcation of vascular perme-
ability factor/vascular endothelial growth factor (VPF/
VEGF, VEGF-A) [19]. However, quantitative measure-
ments can be made by extracting the dye from tissues and
measuring it spectrophotometrically [20]. A limitation of
the Miles assay, whether permeability is assessed visually
or by quantitative measurement, is that it does not distin-
guish between dye that has extravasated from that present
within the vasculature. However, serious error does not
result when intravascular volumes are small relative to the
amounts of dye that have leaked, for example, at skin test
sites injected with column fractions containing different
amounts of VPF/VEGF. Another limitation is that the Miles
assay measures net accumulation of dye–albumin complex
over a period of time and return of extravasated molecules
to the circulation, either by way of capillaries or lymphatics,
is not considered. Despite these limitations the Miles assay
has provided much useful information.
However, in tumors and in other examples of patho-
logical angiogenesis, the vasculature undergoes dramatic
changes and is not comparable to that of adjacent normal
control tissues. In such instances it is important to measure
both the content of tracer within blood vessels and that
which has extravasated. This can be accomplished using a
dual isotope approach [20–22]. Operationally,
125I-albumin
is injected i.v. into a mouse at time zero. After 25 min, a
second i.v. injection is administered, this time of
131I-
albumin. After 5 min, at time 30 min, blood is collected,
animals are euthanized and tissues of interest are harvested,
weighed, and subjected to gamma counting. The following
equations are used to calculate intravascular plasma vol-
ume (Vp) and the albumin leakage rate (LR):
A131 ¼ Cp131   Vp þ LR   Cp131   5
A125 ¼ Cp125   Vp þ LR   Cp125   30
LR ¼ 1=25   A125=Cp125   A131=Cp131

Vp ¼ 1=5   6   A131=Cp131   A125=Cp125

A ¼ Cp   Vp þ LR   Cp   t
where A is total tissue radioactivity (lCi/g) of
125I-albumin
or
131I-albumin; Cp is concentration of radioactive tracer in
plasma (lCi/ll); Vp is volume of plasma in tissue (ll/g);
LR is the leakage rate from plasma into tissue expressed as
ll/min-g and is equivalent to the permeability–surface area
product; and t is time elapsed since injection of tracer
(min).
An underlying assumption of this method is that even in
the case of highly leaky blood vessels only negligible
amounts of
131I-albumin will have had time to extravasate
at 5 min after injection. Therefore, the
131I-albumin value
at 5 min provides a quantitative measure of intravascular
volume whereas the
125I-albumin value provides a measure
of the sum of both intravascular and extravascular albumin.
Extravasated albumin (i.e., the volume of plasma extrava-
sated in 25 min) can then be determined by subtracting the
5 min value from the 30 min value. This method has the
disadvantages of using a strong, short-lived gamma emitter
(
131I) and of not permitting visual inspection of tracer
leakage as when Evan’s blue dye is used as tracer. To
circumvent these limitations we recently modiﬁed the
method by substituting Evan’s blue dye (hence plasma
albumin) for the ﬁrst tracer (30 min time point) and using
125I-albumin for the second (5 min time point).
Fig. 1 Miles permeability assay. Various test substances were
injected intradermally into the shaved and depilated ﬂank skin of a
Hartley guinea pig, followed immediately by an intravenous injection
of Evan’s blue dye. Animal was photographed 30 min later. Injected
materials were as follows: 1, Neutralizing antibody against VEGF-A;
2 and 5, ascites tumor-associated VEGF-A; 3 and 6, ascites tumor
associated VEGF-A plus control immunoglobulin; 4 and 7, ascites
tumor-associated VEGF-A plus speciﬁc VEGF-A neutralizing anti-
body. Reproduced from [93]
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The assays described above measure permeability in living
animals. However, a number of groups have used in vitro
assays to measure the ﬂux of small or large molecules
across lawns of conﬂuent endothelial cells cultured on
membrane ﬁlters in transwell chambers [5, 10, 23–26].
These assays are appealing in that they are relatively easy
to perform and avoid the complexities of studies in living
animals. However, in our view they suffer from severe
limitations. Conﬂuent-cultured endothelial cell monolay-
ers, whether isolated from large or small vessels, are
generally leakier than the normal blood vessel wall in vivo,
perhaps because pericytes or smooth muscle cells that
normally modify endothelial cell behavior are missing.
Also, cultured endothelial cells generally have relatively
few cytoplasmic vesicles and vacuoles, structures which
are numerous in these same cells in vivo and provide the
means by which solutes, and especially proteins, cross
capillary and venular endothelium in vivo. Attempts to
restore these vesicles have only been achieved in cultured
endothelium under specialized conditions that are not
easily amenable to permeability assays [27, 28]. Cultured
endothelial cells are extremely ﬂattened cells that do not
resemble, for example, the cuboidal venular endothelium
that is responsive to permeability agents such as VEGF-A
or histamine in vivo. Finally, the kinetics of leakage in
response to agents such as VEGF-A differ markedly in
vivo and in cultured endothelium. In vivo, leakage in
response to a single exposure to VEGF-A begins within a
minute and is largely complete by *30 min. However,
increased permeability develops much more slowly in
cultured endothelium and often peaks over a period of
hours, suggesting that the permeability observed may
reﬂect, at least in part, a loosening of intercellular con-
nections as endothelial cell are stimulated to migrate by
VEGF-A. In sum, current in vitro assays do not mimic the
basal vascular permeability or acute vascular hyperper-
meability observed in vivo, but may provide a model for
measuring the chronic vascular hyperpermeability charac-
teristic of pathological angiogenesis as found in tumors,
healing wounds, and chronic inﬂammation (see below).
Basal vascular permeability (BVP), acute vascular
hyperpermeability (AVH), and the chronic vascular
hyperpermeability (CVH) of pathological angiogenesis
As was already noted, low levels of vascular permeability
to plasma proteins are essential for the health of normal
tissues and these levels may vary considerably at different
times in different organs and tissues in response to different
physiological stimuli, e.g., exercise. However, it is
important to distinguish between the basal permeability
levels of normal tissues and the greatly increased levels of
plasma protein extravasation that occur in pathology. These
hyperpermeable states may be acute or chronic and differ
from each other and from basal levels of permeability with
respect to the vessels that leak, the composition of the
extravasate, and the anatomic pathways that solutes follow
in crossing vascular endothelium. Each of the three types
of permeability will now be discussed in turn.
Basal vascular permeability (BVP)
Molecular exchange in normal tissues takes place primarily
in capillaries. Indeed, it may be stated that the primary
function of several major organs (heart, lungs, kidneys) and
of larger blood vessels (arteries, arterioles, veins, venules)
is to supply the capillaries, and thus the tissues, with
nutrients and to clear waste products. The molecules
exchanged consist largely of gases (O2 and CO2), water,
small molecules such as salts and sugars, and only small
amounts of plasma proteins. The process is driven largely
by diffusion. The extent of BVP varies considerably in
different normal tissues and is subject to substantial change
in response to changes in hydrostatic pressure, opening of
closed vessels, surface area available for exchange, blood
ﬂow, etc.
How do plasma water and solutes of different size tra-
verse capillaries? As noted above, physiologists have
likened capillary endothelium to a thin, passive barrier
penetrated by pores of varying size. These putative pores
were recognized to be too small to be visualized by light
microscopy. Therefore, there was great excitement that
electron microscopy, as it became available in the 1950s,
would be able to visualize the pores. But these expectations
were not immediately realized. No ‘‘pores’’ as such were
found in normal capillary endothelium. Nonetheless, it was
not difﬁcult to explain the transport pathways followed by
small molecules. Water and lipophilic solutes (e.g., gases
such as O2 and CO2) are able to diffuse through endothelial
cells; they also pass readily through inter-endothelial cell
junctions and through endothelial fenestrae.
1 Small lipo-
philic molecules can also dissolve in endothelial cell
membranes and so pass from the vascular lumen to the
interstitium. However, none of these routes provided a
satisfactory explanation for the passage of large molecules.
Small proteins such as horseradish peroxidase can pass
1 Fenestrae are greatly thinned (70–150-nm diameter) zones of
microvascular endothelium that can be induced by VEGF-A [60].
They are found in small numbers in many types of vascular
endothelium and are especially numerous in specialized vascular
beds that supply tissues that secrete protein hormones. They are
induced in other types of vascular endothelium by VEGF-A[60].
Fenestrae are closed by a thin diaphragm, similar structurally to the
diaphragms closing the stomata found in caveolae and VVOs [29, 34].
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123through inter-endothelial cell junctions, but do so at rates
that are much slower than their entry into tissues [29, 30].
Further, at a MW of 44 kD, HRP is signiﬁcantly smaller
than the smallest plasma proteins such as albumin (MW
69 kD) and therefore does not provide an ideal model for
plasma-protein leakage.
A solution to the problem of plasma-protein extravasa-
tion into normal tissues was offered by George Palade who
observed that capillary endothelium contained large num-
bers of small (*70-nm diameter) vesicles [31–33]. He
named these plasmalemmal vesicles and they are now more
commonly referred to as caveolae (Fig. 2a, b). The
majority of caveolae are found connected to the luminal
and abluminal plasma membranes by means of stomata that
are generally closed by thin diaphragms. Little is known
about the composition of these diaphragms other than that
they contain a unique protein, PV–1, and likely sulfated
proteoglycans [34]. Palade postulated that caveolae shut-
tled across capillary endothelium carrying cargoes of
plasma ﬂuid and proteins and this was subsequently dem-
onstrated experimentally with tracers (reviewed in [29]).
Thus it seemed that the large pores postulated by physi-
ologists were not pores at all but shuttling caveolae and that
transport of large molecules across capillaries was anything
but passive. This concept stood the test of time until quite
recently when it was found that caveolin-1 null mice that
lack capillary endothelial caveolae altogether actually
exhibit increased permeability to albumin [35, 36]. More
will be said about this later.
Acute vascular hyperpermeability (AVH)
A rapid increase in vascular permeability occurs when the
microvasculature is exposed acutely to any of a number of
vascular permeabilizing factors, e.g., VEGF-A, histamine,
serotonin, PAF, etc. Some of these agents (e.g., histamine,
serotonin, VEGF-A) are normally stored in tissue mast
cells [37–39] and so may be released by agents that cause
mast cell degranulation, e.g., allergy, insect bites, etc.
Single exposure to any of these permeability factors results
in a rapid but self-limited (complete by 20–30 min) inﬂux
of plasma into the tissues. Not only is the quantity of
extravasated ﬂuid greatly increased above that found in
BVP but its composition is greatly changed. As already
noted, the ﬂuid passing from the circulation into normal
tissues under basal conditions is a plasma ﬁltrate, i.e., a
ﬂuid consisting largely of water and small solutes but
containing very little plasma protein. However, the ﬂuid
that extravasates in AVH is rich in plasma proteins,
approaching the levels found in plasma, and is referred to
as an exudate. Among the plasma proteins that extravasate
are ﬁbrinogen and various members of the blood clotting
cascade. When these come into contact with tissue factor, a
protein that is normally expressed by many interstitial
cells, the clotting system is activated and the exudate clots
to deposit ﬁbrin [40, 41]. Fibrin forms a gel that traps water
and other solutes, restraining their clearance by lymphatics
or capillaries and resulting in tissue swelling (edema).
Fibrin in tissues has other functions that are discussed
below. However, as long as the permeability stimulus is not
continuous, the deposited ﬁbrin is rapidly degraded without
further consequences.
AVH also differs from BVP in that, as Guido Majno
demonstrated, the vascular leakage takes place not from
capillaries but from post-capillary venules, highly speciﬁc
vessels just downstream of capillaries [42, 43]. Whereas
capillaries have a ﬂattened endothelium, venules are lined
by a much taller, cuboidal endothelium. Majno also pro-
posed a mechanism of protein leakage, namely that
histamine and other vascular permeabilizing agents
induced endothelial cells to contract and pull apart to form
intercellular (paracellular) gaps of sufﬁcient size to permit
plasma-protein extravasation.
More recently, a structure was discovered in venular
endothelium, the vesiculo-vacuolar organelle (VVO), that
offers an alternative, trans-endothelial cell route for plasma
extravasation in response to permeability factors [44–48].
VVOs are grape-like clusters comprised of hundreds of
uncoated, cytoplasmic vesicles and vacuoles that together
Fig. 2 Upper panel: Electron micrograph illustrating a typical
capillary endothelial cell with numerous caveolae. Many of these
are connected to the luminal or abluminal plasma membranes
(arrows), whereas others are in the cytoplasm. L, lumen scale bar,
100 nm. Lower panel: Schematic diagram illustrating pathways by
which molecules can cross the capillary barrier. (1) intercellular cleft;
(2) caveolae that may shuttle across the capillary or form a chain of
vesicles that connect the lumen and albumen. BL, basal lamina
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plasm from lumen to albumen (Figs. 3(a, b), 4a). VVOs
often extend to inter-endothelial cell interfaces and their
individual vesicles (unlike caveolae) commonly open to the
inter-endothelial cell cleft. The vesicles and vacuoles
comprising VVOs vary in size from those the size of
caveolae to vacuoles with volumes as much as 10-fold
larger [49]. These vesicles and vacuoles are linked to each
other and to the luminal and abluminal plasma membranes
by stomata that are normally closed by thin diaphragms
that appear similar to those found in caveolae. We con-
jectured some years ago that VVOs formed from the
linking together of individual caveolae and that larger
vesicles and vacuoles resulted from the fusion of two or
more caveolae-sized vesicles [49]. Evidence for this was
that the smallest VVO vesicles were indistinguishable
structurally from caveolae and larger vesicles and vacuoles
have volumes that do not fall on a continuum but have a
modal distribution, i.e., occur as multiples of the volume of
caveolae, the unit vesicle, up to 10-mers. However, VVO
vesicles and vacuoles only stain irregularly for caveolin
(unpublished data), a protein that is demonstrable by
electron microscopic immunocytochemistry in nearly all
plasma membrane-connected caveolae. Also, whereas the
capillaries in caveolin-1 null mice lack caveolae altogether
[36], VVOs are present in normal numbers in the venular
endothelium of these mice (unpublished data). Whether
VVOs somehow take the place of caveolae in caveolin-1
null mice and thereby contribute to the increased perme-
ability observed in these animals needs to be investigated.
Although very little is known about the mechanisms of
VVO function, it is clear that, upon exposure to histamine,
VEGF-A, etc., macromolecular tracers such as ferritin pass
through a sequence of inter-connected VVO vesicles and
vacuoles from the vascular lumen to the albumen (Fig. 4b)
It seems that vascular permeability inducing agents cause
the diaphragms interconnecting vesicles and vacuoles to
open, thereby providing a transcellular pathway for plasma
and plasma-protein extravasation. The underlying mecha-
nism could be mechanical, as was the endothelial cell
contraction mechanism originally postulated by Majno
[43]. If so, the actin–myosin contractions induced by
Fig. 3 Transmission electron micrographs of venules in normal
mouse ear skin (a, b) and of a mother vessel (c, d) 3 days after local
injection of Ad-VEGF-A
164.( a, b) Typical normal venules lined by
cuboidal endothelium. The cytoplasm contains prominent vesiculo-
vacuolar organelles (VVOs) and is enveloped by a complete coating
of pericytes (P). R, red blood cell. (c, d) MV are greatly enlarged
vessels that are characterized by extensive endothelial cell thinning;
striking reduction in VVOs and other cytoplasmic vesicles; prominent
nuclei that project into the vascular lumen; frequent mitotic ﬁgures
(arrows, c); endothelial cell bridging with the formation of multiple
lumens (L, d); and pericyte (P) detachment in (c). The mother vessel
lumen (c) is packed with red blood cells, indicative of extensive
plasma extravasation. Inset. The normal venule depicted in a is
reproduced in c at the same magniﬁcation as the mother vessel to
illustrate differences in relative size of normal venules and MV. Scale
bars: (a, b) 1 lm; (c, d) 5 lm
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linking adjacent VVO vesicles and vacuoles, resulting in a
transcellular rather than an inter-endothelial cell (paracel-
lular) route for plasma extravasation. Determining whether
solutes cross venular endothelium by inter-endothelial cell
or transcellular (by VVOs) pathways is difﬁcult because of
the tortuosity of inter-endothelial cell borders and the
proximity of VVOs to these borders. Three-dimensional
(3D) reconstructions at the electron microscopic level have
demonstrated that many of the openings induced in venular
endothelium by permeability factors are in fact trans-
endothelial cell pores [48–50].
Chronic vascular hyperpermeability (CVH)
WhereasacuteexposuretoVEGF-Aresultsinimmediatebut
self-limited hyperpermeability of normal venules, chronic
exposureresultsinprofoundchangesinvenularstructureand
function that lead to the chronic hyperpermeability of
pathological angiogenesis
2 as found in tumors, healing
wounds, and chronic inﬂammatory diseases such as rheu-
matoid arthritis, psoriasis, cellular immunity, etc. [1, 2, 51].
As in AVH, the ﬂuid that extravasates is an exudate that
approaches the overall composition of plasma. In tumors
ﬂuid accumulation is generally associated with increased
interstitialpressure [52];thisincreasedpressure resultsfrom
persistent vascular hyperpermeability, clotting of the exu-
datewithdepositionofaﬂuid-trappingﬁbringel,inadequate
lymphatic drainage, and the restraints imposed by sur-
rounding tissues that together limit ﬂuid dissipation.
However, these restraints are nearly absent when tumors
grow in or around body cavities such as the peritoneum
where massive amounts of ascites ﬂuid (many liters) can
accumulate.
In contrast to BVP and AVH, ﬂuid leakage in CVH does
not take place from any type of normal blood vessel.
Instead, whether in tumors or wounds, the blood vessels
that leak are newly formed, highly abnormal angiogenic
blood vessels; these are primarily mother vessels (MV),
and also, to a lesser extent, glomeruloid microvascular
proliferations (GMP) that form from MV [20, 53–57]
(Figs. 3c, d, 4c, 5). Mother Vessels are greatly enlarged
sinusoids that arise from preexisting normal venules by a
process that involves pericyte detachment, vascular basal
lamina degradation, and a 4–5-fold increase in lumen size
that is accompanied by extensive endothelial cell thinning.
Poiseuille’s law indicates that blood ﬂow is proportional to
the fourth power of the vascular radius. Nonetheless, MV
exhibit sluggish blood ﬂow because of their hyperperme-
ability to plasma which results in a striking increase in
hematocrit (Fig. 3c).
As expected, the protein-rich exudates in CVH interact
with tissue factor to trigger the clotting system and deposit
ﬁbrin [40, 41]. Tissue factor is expressed on many tumor
cells as well as host interstitial cells and is induced in
endothelial cells by VEGF-A [58]. In addition to its ﬂuid
trapping properties, ﬁbrin also has a number of other
properties when it persists over time as in tumors and
healing wounds. It provides a pro-angiogenic provisional
stroma that induces and is later replaced by the ingrowth of
new blood vessels and ﬁbroblasts and the laying down of
mature ﬁbro-vascular stroma [2, 17, 59]. Fibrin interacts
with integrins expressed by multiple cell types and so
supports the migration of tumor cells as well as host
mesenchymal cells (endothelial cells, pericytes, ﬁbroblasts)
and inﬂammatory cells (neutrophils, monocytes). Fibrin
Fig. 4 (a) Schematic diagram of a normal venule comprised of
cuboidal endothelium with prominent VVOs and closed inter-
endothelial cell junctions. Note that some VVO vesicles attach to
the intercellular cleft below the tight and adherens junction zones. 1
and 2 indicate potential pathways for transcellular (VVO) and
intercellular (paracellular) plasma extravasation, respectively. Basal
lamina (BL) is intact and the endothelium is completely covered by
pericytes. (b) AVH. Acute exposure to VEGF-A causes VVO to open,
allowing transcellular passage of plasma contents, possibly by
mechanical pulling apart of stomatal diaphragms (3). Others have
suggested that ﬂuid extravasation takes place through an opening of
intercellular junctions (4, here shown closed). BL and pericyte
coverage are as in (a). (c) CVH. Prolonged VEGF-A stimulation
causes venular endothelium to transform into MV, greatly thinned,
hyperpermeable cells with fewer VVOs and VVO vesicles/vacuoles,
degraded BL, and extensive loss of pericyte coverage. Plasma may
extravasate either through residual VVO vesicles (5) or through
fenestrae (6)
2 Although careful measurements have not been made, it is unlikely
that extensive vascular permeability accompanies the angiogenesis of
normal development. At least in later stages of embryonic growth and
post-natally, the developing blood vessels exhibit the structure of
normal adult vessels and do not resemble the chronically permeable
MV found in pathological angiogenesis.
Angiogenesis (2008) 11:109–119 115
123also sequesters growth factors, protecting them from deg-
radation, and induces the expression of proangiogenic
molecules such as IL-8 and tissue factor. Fragment E, a
ﬁbrin breakdown product, is directly pro-angiogenic
(reviewed in [1, 58]).
Macromolecules such as ferritin extravasate from MV
and GMP largely by a transcellular route [20]. As noted
above, MV develop from normal venules by a process that
involves extensive vascular enlargement with consequent
endothelial cell thinning, processes that are thought to be
facilitated, at least in part, by a transfer of VVO
membranes to the plasma membrane [20]. As a result, MV,
as well as the GMP that derive from MV, contain many
fewer and less complex VVOs than normal venular endo-
thelium. However, the path length for molecular
extravasation is greatly shortened as tracers such as ferritin
need to pass through only a few, often only one or two,
vesicles or vacuoles to reach the ablumen (Fig. 3(c, d), 4c,
5b). Macromolecules also extravasate through fenestrae
that are present in both MV and GMP [49] (Figs. 4c, 5c).
Pores of the type that have been described in AVH have
also been found in the endothelial cells of blood vessels
Fig. 5 Electron micrographs of portions of a MV (a) and a GMP (b)
at 5 and 10 days following local injection of Ad-VEGF-A
164 into
nude mouse ears and 30 min after i.v. injection of ferritin tracer. (a)
MV endothelium is greatly thinned and spanned by no more than 1–3
vesicles/vacuoles. Ferritin (dark-black particles) ﬁll vascular lumens
(L), are present in VVO vesicles/vacuoles, and have extravasated into
the extravascular space (some encircled). (b) GMP with extensively
thinned and fenestrated endothelium. Ferritin is present in lumen,
occasional residual cytoplasmic vesicles (white arrows) and in
extravascular space, some encircled. p, pericyte. Scale bars,
200 nm. Reprinted in revised form from [20]
Table 1 Decreased (++), increased (rr), or unchanged (,,) basal, acute, or chronic vascular permeability in various engineered mice
Basal ++ ??
** Caveolin-1 null [36]; [35]; eNOS null [66]; endothelial cell speciﬁc myrAkt TG [67]; PlGF K14 TG
[68]; VEGF-A
164 K14 TG [69]; VEGF-A
120 K14 TG [70]; collagen XVIII null [71]
,, eNOS null [72]; Akt-1 null [64, 73, 74]}; TSP-1 K14 TG [75]; TSP-2 null [76]; b3 integrin null
[77]; HIF-1a K14 TG [78];
Acute, VEGF-A-mediated ++ eNOS null [79]; endothelial cell speciﬁc caveolin-1 TG [80]; Akt-1 null [73]; Src and
Yes null [81]; angiotensin II type 1 receptor null [82]; PlGF null [83, 84]; Ang-1 K14 TG
[69]; sNRP-1 K14 TG [85]; ESAM null [86]; b5 integrin null [87]
** b3 integrin null [77]
,, iNOS null [79]; endothelial speciﬁc myrAkt endothelial cell TG [67]; Fyn null [81];
collagen XVIII null [71]
Chronic, VEGF-A/tumor mediated ++ eNOS null [79]; caveolin-1 null [88, 89]; endothelial cell-speciﬁc cav-1 TG [80];
Akt-1 null [73]; PlGF null [84]
** b3 integrin null and b3/b5 integrin double null [90]; caveolin-1 null [91, 92]
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123supplying tumors [43, 46, 60] (Fig. 4c). As noted earlier,
such openings have often been called intercellular. How-
ever, careful 3D reconstructions of serial electron
microscopic sections have shown that many pores induced
by vascular permeabilizing agents are in fact transcellular
pores that pass through endothelial cell cytoplasm [48, 50].
Molecular and genetic events that regulate vascular
permeability
This review has shown that vascular permeability, far from
being a single, well-deﬁned entity, is instead an extremely
complex process that in different settings, involves dis-
tinctly different types of blood vessels and makes use of
different anatomic pathways. Further, whereas the ﬂuid
extravasating in BVH is a plasma ﬁltrate consisting almost
entirely of water and small solutes, that extravasating in
AVH and CVH, is a protein-rich exudate. Agents such as
VEGF-A have long been known to induce AVH and CVH,
but, apart from hemodynamic factors, much less is known
about the molecular events that are responsible for the
normal permeability of BVP. Even less is known about the
molecules that are involved in regulating permeability,
though this is changing rapidly. In Table 1 we have listed
as many of the published gene products of which we are
aware that have been implicated in vascular permeability.
Some of these molecules have long been known to have
roles in permeability whereas others have only recently
been recognized to have such a role. However, the sig-
naling pathways by which even such well-studied
molecules as eNOS and caveolin-1 act to induce perme-
ability are poorly understood. Almost nothing is known
about the molecular mechanisms that regulate such critical
events as caveolar shuttling, the opening of VVO dia-
phragms, the formation of fenestrae, changes in endothelial
cell junctions, etc. [61–63]. We have attempted to catalog
the molecules in Table 1, as far as is possible with existing
knowledge, under the headings of BVP, AVH, and CVH.
Some of these molecules are clearly involved in all three
types of permeability whereas others apparently are not.
The molecular mechanisms that govern each of the dif-
ferent types of permeability may well be different and are a
subject for further research. As an example, Phung et al.
found that, unlike the AVH induced by VEGF-A, the CVH
found in mice over-expressing myr-Akt in vascular endo-
thelium was not regulated by eNOS [64].
Finally, just as the angiogenic response induced by
VEGF-A differs signiﬁcantly in different mouse strains
[65], it is likely that the permeability response, both basal
and that induced by permeability factors, will also differ in
mice with different genetic backgrounds, though this has
not as yet been investigated in any systematic manner.
Conclusions
This review has provided a framework for measuring
vascular permeability. It has also demonstrated that vas-
cular permeability needs to be considered in at least three
distinctly different settings: BVP, AVH and CVH. These
distinctions are important as it is likely that both common
and different molecular mechanisms are involved in each.
Future work will need to focus on the molecular mecha-
nisms by which the molecules in Table 1, and likely others
yet to be discovered, act to regulate permeability in each of
the three settings.
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